OBJECTIVE: To investigate the impact of the clinical course of the primary HIV infection on the subsequent course of the infection. DESIGN: Prospective documenting of seroconversion, follow up at six month intervals, and analysis of disease progression by life tables. PATIENTS: 86 Men in whom seroconversion occurred within 12 months. PRIMARY OUTCOME MEASURE: Progression of HIV infection, defined as CD4 lymphocyte count less than 0.5 X 10(9)/l, recurrence of HIV antigenaemia, or progression to Centers for Disease Control group IV. MAIN RESULTS: Median follow up was 670 (range 45-1506) days. An acute illness like glandular fever occurred in 46 (53%) subjects. Three year progression rates to Centers for Disease Control group IV was 78% at three years for those who had longlasting illnesses (duration greater than or equal to 14 days) during seroconversion as compared with 10% for those who were free of symptoms or had mild illness. All six patients who developed AIDS had had longlasting primary illnesses. Three year progression rates to a CD4 lymphocyte count less than 0.5 X 10(9)/l and to recurrence of HIV antigenaemia were significantly higher for those who had longlasting primary illnesses than those who had no symptoms or mild illness (75% v 42% and 55% v 14%, respectively). CONCLUSION: The course of primary infection may determine the subsequent course of the infection.
OBJECTIVE: To investigate the impact of the clinical course of the primary HIV infection on the subsequent course of the infection. DESIGN: Prospective documenting of seroconversion, follow up at six month intervals, and analysis of disease progression by life tables. PATIENTS: 86 Men in whom seroconversion occurred within 12 months. PRIMARY OUTCOME MEASURE: Progression of HIV infection, defined as CD4 lymphocyte count less than 0.5 X 10(9)/l, recurrence of HIV antigenaemia, or progression to Centers for Disease Control group IV. MAIN RESULTS: Median follow up was 670 (range 45-1506) days. An acute illness like glandular fever occurred in 46 (53%) subjects. Three year progression rates to Centers for Disease Control group IV was 78% at three years for those who had longlasting illnesses (duration greater than or equal to 14 days) during seroconversion as compared with 10% for those who were free of symptoms or had mild illness. All six patients who developed AIDS had had longlasting primary illnesses. Three year progression rates to a CD4 lymphocyte count less than 0.5 X 10(9)/l and to recurrence of HIV antigenaemia were significantly higher for those who had longlasting primary illnesses than those who had no symptoms or mild illness (75% v 42% and 55% v 14%, respectively). CONCLUSION: The course of primary infection may determine the subsequent course of the infection.
Authors: B F Polk; R Fox; R Brookmeyer; S Kanchanaraksa; R Kaslow; B Visscher; C Rinaldo; J Phair Journal: N Engl J Med Date: 1987-01-08 Impact factor: 91.245
Authors: J N Weber; J Wadsworth; L A Rogers; O Moshtael; K Scott; T McManus; E Berrie; D J Jeffries; J R Harris; A J Pinching Journal: Lancet Date: 1986-05-24 Impact factor: 79.321
Authors: K C Anderson; B C Gorgone; R G Marlink; R Ferriani; M E Essex; P M Benz; J E Groopman Journal: Ann Intern Med Date: 1986-10 Impact factor: 25.391
Authors: J J Goedert; R J Biggar; M Melbye; D L Mann; S Wilson; M H Gail; R J Grossman; R A DiGioia; W C Sanchez; S H Weiss Journal: JAMA Date: 1987-01-16 Impact factor: 56.272
Authors: D A Cooper; J Gold; P Maclean; B Donovan; R Finlayson; T G Barnes; H M Michelmore; P Brooke; R Penny Journal: Lancet Date: 1985-03-09 Impact factor: 79.321
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Elizabeth Connick; Ronald J Bosch; Evgenia Aga; Rick Schlichtemeier; Lisa M Demeter; Paul Volberding Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Vinícius B Péterle; Jéssica de O Souza; Fernanda de O Busato; Frederico J Eutrópio; Gisele de A P da Costa; David N Olivieri; Carlos E Tadokoro Journal: J Clin Lab Anal Date: 2018-01-04 Impact factor: 2.352
Authors: C Mandelli; D Conte; R Barbera; T Masullo; S Pistoso; G P Aimo; L Cesarini; M Fraguelli; G P Lorini; P A Bianchi Journal: Eur J Epidemiol Date: 1991-01 Impact factor: 8.082
Authors: Philip J Norris; Brandee L Pappalardo; Brian Custer; Gerald Spotts; Frederick M Hecht; Michael P Busch Journal: AIDS Res Hum Retroviruses Date: 2006-08 Impact factor: 2.205
Authors: Paul Volberding; Lisa Demeter; Ronald J Bosch; Evgenia Aga; Carla Pettinelli; Martin Hirsch; Mary Vogler; Ana Martinez; Susan Little; Elizabeth Connick Journal: AIDS Date: 2009-09-24 Impact factor: 4.177